manilatimes1d
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...
News Medical3d
AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
Nasdaq5d
AIM ImmunoTech Inc. Initiates Plan to Advance Ampligen as Vaccine Adjuvant for Avian Influenza
AIM ImmunoTech Inc. announced plans to advance its drug Ampligen as a vaccine adjuvant for avian influenza, marking a new initiative in its antiviral development pipeline. The company has ...
Bills targeting vaccines struggle at the Indiana Statehouse
The bills would restrict how employers treat vaccination and require a reporting system for "vaccine injuries." ...
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...
Investing5d
AIM ImmunoTech advances Ampligen for avian influenza vaccine
AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral priority development pipeline. The company has enlisted the ...
Investing5d
AIM ImmunoTech advances Ampligen for avian influenza vaccine
Investing.com -- AIM ImmunoTech (NYSE:AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...